Actelion - Compensation Committee

Armin Kessler - Chairman of the Compensation Committee
Armin M. Kessler served as Chief Operating Officer of Hoffmann-La Roche in Basel Switzerland from 1990 to 1995. Prior to being appointed COO, he held several senior positions at Hoffmann-La Roche, including head of the pharmaceutical and diagnostic divisions of the organization. Earlier positions in his career included Director of Pharmaceutical Marketing Worldwide for Sandoz (now Novartis) and President of Sandoz KK in Tokyo. He currently serves on the board of The Medicines Company, Gen_Probe and Spectrum Pharmaceuticals (formerly Neotherapeutics) and has served on the boards of Hoffmann-La Roche, Syntex and Genentech. He received a degree in Physics and Chemistry from Pretoria University in South Africa, a degree in Chemical Engineering from the University of Cape Town, South Africa, a Juris Doctorate from Seton Hall University, New Jersey, and Dr. h.c. in Business Administration from the University of Pretoria.

Werner Henrich - Chairman of the Board of Basilea Pharmaceutica
Werner Henrich was born 1943 and is a French citizen. He has an education as a chemist and European patent attorney. He worked for F. Hoffmann-La Roche Ltd. (“Roche”) in Basel for more than 30 years. Mr. Henrich held various positions at Roche including Head of Global Intellectual Property and Pharmaceutical Licensing for more than 12 years. He was also a member of the Roche Pharmaceutical Division Executive Board. In this function Mr. Henrich was responsible for intellectual property activities of all Roche divisions and for major pharmaceutical transactions including research collaborations, patent settlements, licensing-in and -out as well as product acquisitions. He retired from Roche in November 2003. Mr. Henrich has a wide experience in the pharmaceutical industry both with start-ups and large pharmaceutical companies. Mr. Henrich is Chairman of the board of Basilea Pharmaceutica Ltd. and a member of the board of directors of Actelion Ltd., Allschwil and Addex Pharmaceuticals Ltd., Geneva, Swiss biopharmaceutical companies listed on the SWX Swiss Exchange. He acts as a consultant for several biopharmaceutical companies on a part-time basis.

Robert Cawthorn - Chairman of the Board
Robert E. Cawthorn is an investor in Actelion and Chairman of the Board of Directors. Robert Cawthorn has a unique and successful track record of over 35 years in the pharmaceutical industry, which includes establishing start-ups and managing large pharmaceutical companies. Following his retirement as Chairman and CEO of Rhô-Poulenc-Rorer, Inc., he was a managing director of Global Health Care Partners, DLJ Merchant Banking. After 17 years as an executive with Pfizer International, he became the first president of Biogen and was active in creating the foundations for the future success of the company. He joined the Rorer Group in 1982 and, as Chairman and CEO, led the transformation of Rorer from a small, primarily over-the-counter pharmaceutical company into a major research-driven company, culminating in the merger that created Rhône-Poulenc-Rorer.